Cancers develop and progress via activation of oncogenes and loss of tumor suppressor genes, a progression that can be recapitulated through cross breeding mouse strains harboring genetic mutations. To de®ne the role of RET/PTC3, p53 and Fhit in thyroid carcinogenesis, we intercrossed RET/PTC3 transgenics with p537/7 mice. This new strain, RET/PTC3 p537/7
Introduction
The high incidence of thyroid dysfunction (Canaris et al., 2000) warrants a better understanding of the molecular basis of diseases involving thyroid epithelial cells. In the case of thyroid epithelial malignancy, the age of the patient is a major factor determining long term prognosis, suggesting that accumulated mutations observed in nondividing thyroid cells is critical for both dierentiated and undierentiated tumor development. On the basis of histopathological criteria, three major types of thyroid carcinoma exist: medullary, follicular or papillary. Papillary thyroid carcinoma (PTC), comprising 80% of these neoplasms, is a slow-growing, frequently multicentric tumor that breaches the thyroid capsule and metastasizes to paratracheal lymph nodes 50% of the time (Becker, 1995; Braverman and Utiger, 1995) . The multicentric nature of this tumor suggests that tumor spread occurs from intrathyroidal metastasis of a clonal population of cells or as consequence of multiple tumors arising independently. This latter mechanism is reminiscent of the`®eld cancerization' eect in which entire regions of tissue may be altered by mutagen exposure, thereby explaining the frequent synchronous nature of some primary tumors observed in malignancies of the aerodigestive tract (Papadimitrakopoulou et al., 1996) .
The mechanisms governing the transformation of normal thyroid cells into carcinoma are not well understood. Studies have shown that double-stranded chromosomal breaks predominate following ionizing radiation exposure, leading to the formation of fusion genes (Mizuno et al., 1997) . Thyroid epithelium is the second most common tissue type, after blood, where fusion gene products are critical for the early development of cancer (Mizuno et al., 1997) . In PTC, the c-RET gene on chromosome 10 is frequently inverted or translocated to form the predominating fusion genes RET/PTC1, RET/PTC2 or RET/PTC3 which share similar structural features (Corvi et al., 2000; Giannini et al., 2000; Mayr et al., 1999; Yokota et al., 2000) . More recently, fusion gene variants have been isolated bringing the number of RET/PTC gene family members to nine Salassidis et al., 2000) In the cases studied, RET/PTC gene fusions occur within introns juxtaposing the coding region of the c-RET carboxy-terminal kinase domain with the amino-terminal region from one of several constitutively expressed genes (Jhiang and Mazzaferri, 1994 ). The precise function of the RET/PTC genes in tumorigenesis is not clear, though the activation of mitogenic pathways via binding of SH2-containing adapter proteins has been demon-strated in vitro (Arighi et al., 1997; Califano et al., 1995; Durick et al., 1996; Pandey et al., 1995; Santoro et al., 1993) . The unique expression of RET/PTC fusion protein in thyroid cells suggests a selective role in cancer development. Indeed, the formation of RET/ PTC fusion genes may re¯ect the proximity of the partner genes in the nucleus (Nikiforova et al., 2000) . In addition, RET/PTC genes are speci®cally selected for and persist early in thyroid carcinogenesis even under conditions that transiently induce a variety of other fusion genes such as BCR/ABL (Mizuno et al., 1997) . Consistent with these data, RET/PTC proteins are speci®c for papillary carcinoma since no other carcinoma subtypes express them (Jhiang and Mazzaferri, 1994) . A high frequency (460%) and multiplicity (Wirtschafter et al., 1997) of RET/PTC fusion gene expression has been detected in young patients and in smaller dierentiated tumors suggesting that fusion genes are activated early in the disease process and may precede cancer by many years.
These data suggest that RET/PTC fusion genes alone are insucient to cause overt cancer and likely require the simultaneous or accumulated action of multiple gene products for tumors to progress from early dierentiated stages to undierentiated stages of neoplasia. Since dominant oncogenes often cooperate with mutant tumor suppressor genes to disrupt normal cellular growth, survival, and/or dierentiation, they are often co-expressed in cancer (Hunter, 1997) . Accordingly, Tpr53 (p53) and FHIT tumor suppressor gene mutations have been found in both dierentiated and undierentiated thyroid carcinomas (Chang et al., 1998; Duh and Grossman, 1995; Zou et al., 1999) .
p53 is a nuclear localized, DNA-binding phosphoprotein known to aect proliferation in response to cellular damage (Kern et al., 1991) . The function of p53 in promoting tumor formation is thought to involve both the loss of apoptotic control and the disruption of chromosomal stability. Transfection of a mutated p53 gene into thyroid cells can alter the response to DNA damage and the expression of dierentiation markers such as thyroglobulin (Battista et al., 1995) . However, expression of mutant p53 alone does not alter tumorigenic potential and may be insucient to cause a fully developed malignancy (Battista et al., 1995) . Other genetic changes found in undierentiated anaplastic carcinomas include loss of the tumor suppressor gene FHIT (Marchetti et al., 1998; Pellegrini et al., 1999; Sozzi et al., 1998) . Indeed, loss of heterozygosity on chromosome 3p involving the FHIT gene has been associated with both benign and malignant thyroid lesions suggesting that FHIT alterations may be an early event in thyroid carcinogenesis (Chang et al., 1997; Zou et al., 1999) . However, some reports do not support an association between FHIT loss and the stage, histological grade or outcome in human thyroid cancer (McIver et al., 2000) . Thus the role of FHIT in thyroid cancer progression remains controversial.
Sequential gene loss during thyroid tumor progression has not been clear (Mueller et al., 2000) . In addition, the critical period for tumor suppressor loss is not known since mutations have been found in both dierentiated (Pisarchik et al., 2000) and undierentiated cancers (Fagin et al., 1993) . With regard to mice developing dierentiated thyroid cancer, distinct pathological dierences exist between RET/PTC3 (Powell et al., 1998) , RET/PTC1 (Jhiang et al., 1996; Santoro et al., 1996) , and TRK-T1 transgenic mice (Russell et al., 2000) but none of these tumors progress to poorly dierentiated forms unless crossed with p537/7 mice (La Perle et al., 2000) . However, the stage of dierentiation and the continued oncogene expression during thyroid tumor progression has not been fully addressed in vivo and the immunogenicity of these advanced tumors was not known.
RET/PTC3 oncogenes are more prevalent and associated with more aggressive forms of cancer than other RET rearrangements in radiation-induced thyroid carcinomas (Bounacer et al., 1997) . In addition, RET/PTC3 fusion gene expression predominates in patients with Hashimoto's disease (Wirtschafter et al., 1997) suggesting that RET/PTC3 might play an important role in inducing immune responses in vivo. However, RET/PTC fusion proteins have not been detected in advanced human thyroid cancers and few advanced thyroid tumors are associated with evidence of immune responsiveness. Thus, to study the hosttumor interactions in advanced thyroid cancers, we developed a transgenic mouse expressing RET/PTC3 in the thyroid (Powell et al., 1998) . Unfortunately, the dierentiated tumors from RET/PTC3 transgenic mice do not progress to advanced, poorly dierentiated stages and tumors from these mice fail to grow following transplantation into SCID or normal mice. Consequently, we hypothesized that the loss of p53 tumor suppressor function together with the expression of the dominant RET/PTC3 oncogene would lead to poorly dierentiated thyroid carcinomas. These tumors would allow us to examine the role of oncogenes and tumor suppressor genes in thyroid tumor progression and evaluate the immunogeniticty of advanced thyroid cancers.
Results

Progressive thyroid neoplasia in RET/PTC3 p537/7 mice
We have previously demonstrated that the thyroid speci®c expression of the RET/PTC3 transgene causes the development of thyroid follicular cell hyperplasia followed by secondary hyperplasia and microcarcinoma in a majority of transgenic mice by 3 months of age (Powell et al., 1998) . Solid type dierentiated thyroid carcinomas develop by 8 months in 30% of the mice (Powell et al., 1998) resulting in a sixfold increase in weight and larger organ size compared to wild type controls ( Figure 1 ). Only dierentiated carcinomas were found, re¯ecting the need for the alteration of additional genes in the progression of thyroid cancer. Furthermore, recent studies are consistent with a role of p53 gene loss in a similar mouse model (La Perle et al., 2000) . To explore this possibility, we crossed RET/ PTC3 transgenic mice with mice null for the p53 gene (Donehower et al., 1992) . Intercrosses of RET/PTC3 transgenic and p537/7 mice followed by continued brother-sister mating amongst compound heterozygotes resulted in a new strain RET/PTC3 p537/7
. Although p537/7 parental strain mice develop primary neoplasms by 6 months of age, the majority are either sarcomas or lymphomas, and none originate from the thyroid follicular epithelium (Donehower et al., 1992; Thompson et al., 1995) . Interestingly, RET/ PTC3 p537/7 mice developed large palpable neck masses (Figure 1a) , which increased in size until animals died or became moribund at a mean age of 26.3+2.2 weeks (P50.0001). Of those animals that died or became moribund, 52% harbored large thyroid tumors. Some moribund mice with thyroid tumors (20%) also developed thymic masses consistent with the phenotype of the p537/7 parental strain (Donehower et al., 1992; Thompson et al., 1995) . The thyroid tumors that developed in the moribund RET/PTC3 p537/7 mice weighed 45 times more than those from the parental RET/PTC3 strains and grew to an average weight 285 times greater than wild type mouse thyroids ( Figure  1b) . Despite their large tumor burden we ®nd that RET/PTC3 p537/7 tumor-bearing animals rarely developed local lymph node metastases (1/11 mice), an occurrence similar to that observed in the parental RET/PTC3 transgenics (Powell et al., 1998) . These data suggested that the thyroid tumors arising in RET/ PTC3 p537/7 mice were more proliferative and lacked frequent metastases like the parental RET/PTC3 strain.
Continuous growth of RET/PTC
p537/7 thyroid tumors transplanted into SCID, but not normal mice p537/7 mouse strains. Average weights for each group are shown. RET/PTC3 thyroids were signi®cantly larger than wild type (P50.0001). In addition, RET/PTC3 p537/7 thyroids were larger than both wild type (P50.075) and RET/PTC3 thyroids (P50.078). S.e.m. for wild type, RET/PTC3 and RET/PTC3 p537/7 groups were +0.10, 0.42 and 329.30 mg respectively mice is not likely due to antigen loss since these transplanted tumors fail to grow in syngeneic recipients.
Histopathological analysis of developing and established thyroid tumors
To evaluate the microscopic changes that occur during the early stages of thyroid tumor development, we analysed thyroids from RET/PTC3 p537/7 mice starting at 5 weeks of age (not shown). Thyroids from RET/ PTC3 p537/7 mice showed signi®cant pathological changes, including those previously described (Powell et al., 1998) for the 6 ± 8 month old RET/PTC3 mice ( Figure 3b ). This included primary and secondary hyperplasia and microcarcinoma similar to that observed in humans (Rosai et al., 1990) . As early as 3 months of age thyroid tissue examined from RET/ PTC3 p537/7 mice revealed small regions of papillary carcinoma in tight bundles (Figure 3c ). These tumors varied in their appearance, ranging from typical solidtype carcinomas characteristic of the parental RET/ PTC3 mice or classical papillary carcinomas ( Figure  3c ), to regions with sarcomatous features commonly associated with poorly dierentiated human thyroid caricnomas (Rosai et al., 1990) . Between 6 and 8 thyroid tumors possessed morphologic characteristics reminiscent of features observed in human papillary, follicular and anaplastic carcinomas. Such features include papillary extensions, numerous irregular follicles and solid sheets of sarcomatous undierentiated carcinoma ( Figure  3e ,f). Tumors (3 ± 8 months old) developed undierentitated portions of the tumor composed of heterogeneous populations of spindle-shaped cells, which showed mitotic ®gures, loss of polarity and exhibited large, diuse and multiple hyperchromatic nuclei (Figure 3d ). Moreover, these tumors exhibited pseudoglandular patterns with high mitotic activity and large necrotic foci similar to human giant cell anaplastic carcinomas (Rosai et al., 1990) . However, unlike human anaplastic carcinoma or tumors from RET/PTC1+p537/7 mice (La Perle et al., 2000) , RET/PTC3 p537/7 tumor cells rarely penetrated the capsule, invaded extrathyroidal structures or metastasized.
Reduced expression of RET/PTC3 protein in thyroid tumors from RET/PTC3 p537/7 mice
To assess the role of RET/PTC3 in tumor progression, we evaluated RET/PTC3 protein expression using antibodies speci®c for the RET kinase domain and immunohistochemical staining. Lesions taken from 3 ± 6 months old RET/PTC3 p537/7 mice displayed staining for the RET/PTC3 protein (Figure 3e ), while tumor tissue taken from older mice (46 months) showed diminished or undetectable levels of RET/ PTC3 protein expression (Figure 3f ). In all, 43% (6/14) of the RET/PTC3 p537/7 thyroid tumors showed regional loss of RET/PTC3 protein in greater than 50% of the specimen compared to RET/PTC3 transgenic thyroid controls which show 100% expression of the transgene in all specimens. The loss of RET/PTC3 protein expression appeared randomly throughout the specimen independent of the tumor morphology.
Loss of differentiated markers in tumors from RET/PTC3 p537/7 mice
Since the bovine thyroglobulin promoter controls RET/ PTC3 transgene transcription, we evaluated the endogenous thyroglobulin expression in advanced tumors from RET/PTC3 p537/7 mice. Indeed, thyroglobulin expression is lost in RET/PTC3 (Figure 4a ), consistent with an inhibitory eect on the thyroglobulin promoter and characteristic of the loss observed in undierentiated thyroid tumors in humans harboring p53 mutations (Fabbro et al., 1994; Moretti et al., 1997) . Furthermore, the loss of thyroglobulin expression observed by Western blot (Figure 4a ) was con®rmed by the absence of cDNA ampli®ed in this RT ± PCR assay. To con®rm the loss of dierentiation in thyroid tumors we assessed the expression of additional thyroid dierentiation markers by semiquantitative RT ± PCR. Expression of mRNA for thyroglobulin, thyroid peroxidase and TSH receptor was detected in normal and RET/PTC3 thyroid tissue but not in tumors from RET/PTC3 p537/7
mice. Consistent with the reduction of RET/PTC3 protein, the mRNA for RET/PTC3 was reduced, but detectable, in RET/PTC3 p537/7 tumors (Figure 4b ). In contrast, the Pax8 transcription factor mRNA was detected in all specimens.
Regional loss of Fhit protein expression in thyroid tumors
The high frequency of FHIT loss in poorly dierentiated human thyroid carcinomas suggested that poorly dierentiated thyroid tumors arising in RET/PTC3 p537/7 mice might lose Fhit protein expression. Consequently, we determined the level of Fhit protein in dierentiated vs poorly dierentiated tumors arising in RET/PTC3 or RET/PTC3 p537/7 mice respectively. Antibodies speci®c for murine Fhit were used to measure protein expression using immunocytochemical staining. Figure 5 shows representative staining patterns of thyroid tumors derived from RET/PTC3 p537/7 mice. Thyroids examined from mice 53 months old show a high Fhit protein expression (Figure 5a ). By 6 months of age regional Fhit loss was evident (Figure 5b (Birrer et al., 1999; Gatalica et al., 2000; Hao et al., 2000; Manning et al., 1999; Mori et al., 2000; Xiao et al., 1997; Yoshino et al., 2000) . Similar to RET/PTC3 staining patterns within tumors, no morphological dierences were observed between Fhit positive and negative regions indicating that the appearance of the tumor is not a consequence of Fhit protein loss.
Thyroid carcinomas from RET/PTC3
Fhit7/7 and RET/ PTC3 mice are histopathologically indistinguishable
To investigate the relevance of Fhit gene loss in poorly dierentiated thyroid carcinomas, RET/PTC3 transgenic mice were intercrossed with Fhit de®cient mice, Fhit7/7 (Dumon et al., 2001; Fong et al., 2000) . Thyroid abnormalities have not been reported in Fhit7/7 mice nor have we observed abnormalities by histopathological examination of thyroids from 6-month-old Fhit7/7 mice compared to wildtype controls (not shown). RET/PTC3 Fhit7/7 mice were viable and lacked observable neck masses observed in RET/PTC3 p537/7 mice. Histopathological analysis of thyroids resected from 6-month-old RET/PTC3 Fhit7/7 mice ( Figure 5h ) revealed a dierentiated tumor phenotype similar to that observed in RET/PTC3 parental strain mice (Figure 5g ). Even in mice aged up to 1 year, invasive or poorly dierentiated thyroid carcinomas were not observed in any of the RET/ PTC3 Fhit+/7 (0/6) or RET/PTC3 Fhit7/7 mice (0/11).
Discussion
Malignant transformation requires multigenic mutational events. The relationship between dierentiated and undierentiated thyroid tumors is not understood and remains controversial. The analysis of thyroid tumors that develop in RET/PTC3 p537/7
or RET/ PTC1+p537/7 mice (La Perle et al., 2000) , have revealed an important role of p53 gene loss in the progression of dierentiated thyroid cancer into an advanced poorly dierentiated malignancy. Although on dierent genetic backgrounds and constructed with distinct RET/PTC family members, these mice develop similar malignancies. However, the RET/PTC3 p537/7 mouse provides a good model to study the host response in the development of anaplastic carcinoma. Indeed, the use of the B6C3F 1 background has helped to de®ne the host response to this experimental cancer since transplants of RET/PTC3 p537/7 grew in immunode®cient but not normal mice. This ®nding suggests that immunogenic antigens exist on RET/PTC3 p537/7 tumors. Future studies will help de®ne such antigens in human cancers. This is important since immune in®ltrates are frequently associated with human papillary thyroid carcinoma (Okayasu et al., 1995) . In addition, the de®ned loss of thyroid speci®c markers and Fhit protein is consistent with previous studies using undierentiated and anaplastic thyroid cell lines (Chen et al., 2000; Shi et al., 1993; Zou et al., 1999) .
The synergism between RET/PTC3 and p53 in the formation of tumors in RET/PTC3 p537/7 mice indicates that these two pathways cooperate in the progression of thyroid cancer. Although the precise mechanism is thyroid carcinomas. Even though repression or loss is likely due to intrinsic eects on the thyroglobulin promoter, these data unequivocally indicate that high levels of RET/PTC3 protein expression are not required for the proliferation and outgrowth of poorly dierentiated malignancies and may explain the absence of RET/PTC in poorly dierentiated and undierentiated human thyroid carcinomas (Tallini et al., 1998) . This suggests that continued RET/PTC expression may be inhibitory and its loss required for tumor progression.
The reason for RET/PTC loss is not known but may involve the need for altered kinase-signaling pathways in thyroid cells as they develop from dierentiated into undierentiated tumors. RET/PTC may trigger quiescent thyroid epithelium to enter the cell cycle and activate mitogenic and pro-apoptotic signaling cascades. The activation of both NF-kB (pro-apoptotic) and RAS (mitogenic) signaling pathways in dierentiated thyroid cancers is consistent with this notion (Duh and Grossman, 1995; Ivan et al., 1997; Visconti et al., 1997) . The loss of apoptotic control due to p53 gene mutation may lead to unabated cell growth in the absence of cell death and obviate the need for continued RET/PTC expression. Furthermore, immune recognition of RET/PTC transformed thyroid tissue may place negative selection pressure on dierentiated tumors. Consistent with this we (Wirtschafter et al., 1997) and others (Sheils et al., 2000) ®nd expression of RET/PTC in a majority of patients with Hashimoto's autoimmune thyroiditis. These data indicate the presence of premalignant thyroid cells, whereas the frequency of RET/PTC expression is reduced in overt cancer (Sugg et al., 1998) .
The oncogenic activation of RET/PTC appears early in thyroid carcinogenesis , however there is considerable controversy concerning when p53 mutations arise during thyroid tumor development (Komminoth, 1997; Qin et al., 1999; Soravia et al., 1999; Zou et al., 1993) . Preexisting or concurrent mutations caused by radiation exposure have been identi®ed in thyroid cancers (Pisarchik et al., 2000) . These cancers also show a high rate of RET/ PTC3 activation (Nikiforov et al., 1997) . In addition, cultured cells harboring p53 mutations were unable to grow when transplanted in vivo (Battista et al., 1995) , suggesting that the timing of p53 mutation is a crucial step in tumor progression. Other experiments have shown that p53 aects proliferative capabilities of thyroid cells in vitro (Moretti et al., 1997) . The synergistic result of p53 loss and RET/PTC3 activation in the progression of thyroid tumors likely involves both growth promoting and apoptosis inhibiting pathways.
We hypothesize that loss of p53 function leads to genome destabilization promoting the development of additional mutations. Alternatively, p53 gene loss may lead to deregulation in apoptotic pathways, shifting the balance between the anti-apoptotic and pro-apoptotic RET/PTC3 induced signals. The possibility that genomic instability results from p53 gene loss suggested that other mutations might be induced by the loss of p53. We chose to investigate the loss of Fhit in thyroid tumors for three reasons: (i) Fhit is located in a chromosomal fragile site and may re¯ect genome wide changes (Glover et al., 1998) ; (ii) The human FHIT protein is lost in a majority of head and neck cancers, and mutations have been detected in both dierentiated and undierentiated carcinomas of the thyroid (Chang et al., 1998; Virgilio et al., 1996; Zou et al., 1999); and (iii) No data exist relating coincident p53 and Fhit loss in thyroid cancer or their combined eect on cancer progression. We ®nd high expression of Fhit in small carcinomas detected in young RET/PTC3 p537/7 mice (53 months old) but extensive loss in tumors derived from mice 46 months old, indicating that Fhit loss in this animal model is a late event. Although Fhit loss is detected in RET/PTC3 p537/7 tumors that retain dierentiated morphology, they have lost thyroid speci®c markers such as thyroglobulin, thyroid peroxidase and thyroid stimulating hormone receptor, consistent with poorly dierentiated thyroid carcinomas (Chen et al., 2000; Shi et al., 1993) . The loss of Fhit protein in murine tumors was independent of tumor histology, similar to Fhit expression in human thyroid tumors (McIver et al., 2000) . In this murine study however, Fhit loss progresses, consistent with the frequent loss of FHIT in late-stage poorly dierentiated human anaplastic thyroid carcinomas (Zou et al., 1999) but in contrast to reports of FHIT gene loss early in thyroid tumor development (Chang et al., 1998) . The reason for these dierences is not clear but may involve species-or organ-speci®c dierences or disparities between the origin of the p53 and RET/ PTC3 mutations in these studies (transgenesis) compared to human disease (somatic mutation). Whether Fhit loss in poorly dierentiated thyroid carcinomas has functional relevance is unclear, however, we do not observe thyroid abnormalities in Fhit7/7 mice and thyroid tumors from RET/PTC3 Fhit7/7 mice fail to progress beyond the dierentiated state observed in the RET/PTC3 parental strain (Powell et al., 1998) .
The ®nding of Fhit loss in a majority of the larger thyroid carcinomas, irrespective of tumor pathology, suggests that tissue appearance and growth behavior/ gene expression are disconnected at these stages of malignant growth. In accordance with this idea, FHIT and p53 gene loss may occur prior to loss of (Arezzo et al., 1998; Carcangiu et al., 1985; Vinette et al., 1991) . These aicted patients may be at high risk for tumor spread, invasion, and metastatic tumor growth. Supportive evidence of this comes from experiments demonstrating neoplastic transformation of primary normal human thyroid cells following RAS transfection. In these cultures, expression of an activated RAS protein leads to proliferation but retention of dierentiated features such as thyroglobulin expression (Gire and Wynford-Thomas, 2000) . A hypothetical model of gene acquisition and loss during the development of human thyroid carcinoma is shown in Figure 6 . In this model early dysplastic or neoplastic lesions express high levels of RET/PTC, or other thyroid speci®c oncogenes that initiate cell cycle progression (proliferation and apoptosis). This is followed by thyroid oncogene loss or reduction leading to a less dierentiated and proliferative stage coincident with the loss of p53 function (or activation of dominant negative protein) that promotes progression to poorly dierentiated stages. The progressive loss of Fhit expression coincides with the development of undierentiated carcinoma due to an unknown in vivo selection mechanism. The spontaneous development of thyroid tumors in RET/PTC3 mice in comparison to the advanced malignancies observed in the RET/ PTC3 p537/7 mice makes it possible to test this model and assess the role of speci®c gene defects in cancer progression. The ®nding that gene loss/gain can be disconnected from histopathological features has direct implications in tumor diagnosis and treatment. We ®nd that sections of tumor tissue that look dierentiated may have genetic features of undierentiated tumors. Likewise regions of the tumor that appear poorly dierentiated may express genes similar to dierentiated thyroid carcinomas. Thus, the molecular pathways responsible for the uncoupling of dierentiation, tumor growth and spread in RET/PTC3 p537/7 mice may be studied using tissue from both dierentiated and undierentiated regions. Reintroduction of wild type p53 into undierentiated thyroid tumors induced dierentiated features in transfected cells (Moretti et al., 1997) . Moreover, the selection pressures on neoplastic cells which may profoundly dier in vitro and in vivo are only apparent following tumor growth in animals as illustrated by the loss of Fhit from human chromosome 3/mouse ®brosarcoma microcell hybrids after passage of cells in SCID mice (Kholodnyuk et al., 2000) . Consequently future experiments using gene targeting strategies in RET/PTC3 p537/7 thyroids will help resolve the role RET/PTC3, p53 and Fhit play in of undierentiated thyroid tumor development.
Materials and methods
Mice
RET/PTC3 transgenic mice (3209 line) were generated as previously described (Powell et al., 1998) . For breeding Figure 6 A model of human thyroid progression from dierentiated to poorly dierentiated malignancy. Each . represents presence of the gene product in *25% of the cells of the tumor; each * represents loss of the gene product in *25% of the cells of the tumor. Activation of the RET/PTC oncoprotein in malignant lesions is followed by its progressive loss during the transition from dierentiated to poorly dierentiated thyroid cancer. This step coincides with the progressive loss of p53 and Fhit tumor suppressor proteins during the continued development to undierentiated carcinomas. The change in organ color (light to dark) represents the progressive loss of thyroid dierentiation markers within tumor cells and the increased invasiveness of these cells as the malignancy (circular nodule) progresses and RET/ PTC3 Fhit7/7 homozygotes, respectively. Progeny were genotyped using p53, RET/PTC3, and Fhit speci®c polymerase chain reaction (PCR) as described below. SCID mice (Jackson Laboratories) were used for the growth of transplanted thyroid tumors.
Tail DNA amplification by PCR
Transgenic and null mutant mice were genotyped using PCR with RET/PTC3 and Fhit speci®c primers using published protocols and sequences (Fong et al., 2000; Powell et al., 1998) . Additional primer sequences for the detection of p53 wild type and null mutant allele were as follows: p53 wt allele, 5' primer GTGTTTCATTAGTTCCCCACCTTGAC, and 3' primer, ATGGAGGGCTGCCAGTCCTAACCC; p53 null mutant allele, 5' primer, GTGGGAGGGA-CAAAAGTTCGAGGCC, and 3' primer, TTTACG-GAGCCCTGGCGCTCGATGT. Brie¯y, 100 ng of mousetail genomic DNA was added to 50 ml reaction mixture containing 16PCR buer (Boehringer-Mannheim Biochemicals), 0.2 mM dNTPs, 50 pM oligonucleotides and 2.0 UTaq polymerase (Ausubel et al., 1995) . The specimens were then placed into a heated lid thermocycler (Hybaid, Inc.) and subjected to 30 cycles of denaturation at 948C for 30 s, annealing at 608C for 30 s (or 558C for 30 s for p53 primers), and elongation at 728C for 60 s. PCR products were resolved on 2% agarose gels, visualized by ethidium bromide staining and recorded using a Bio-Rad Chemi-Doc System TM (BioRad Laboratories).
Semi-quantitative RT ± PCR analysis
Thyroid tissue was removed from transgenic mice and homogenized in 0.5 ml of cell lysis buer (44 M Guanidinium thiocyanate, 25 mM Sodium citrate, 0.5% Sodium Nlauroylsarcosine, 0.1 M 2-mercaptoethanol) using a mechanical homgenizer (Biospec Products, Racine, WI, USA). Protein was removed using phenol: chloroform extraction (1 : 1), while nucleic acid was recovered following ethanol precipitation. DNA was removed using RNAse free DNAse (Ambion). Five mg total RNA isolated from RET/PTC3, RET/PTC3 p537/7 transgenic and nontransgenic mouse thyroid was reverse transcribed (Superscript II, Gibco ± BRL) and cDNA ampli®ed in a semi-quantitative PCR after cDNA had been normalized using primers speci®c to glyceraldehyde-3-phosphate dehydrogenase (G3pdh). PCR reactions were performed as detailed above. The murine G3pdh speci®c PCR primers were 5' primer CCTTCATTGACCTCAAC-TAC and 3' primer ATGACAAGCTTCCCATTCTC. Semiquantitative PCR was then performed utilizing murine primers speci®c for thyroglobulin (5' primer CCTGGTCTTGTGGGTCTCTA and 3' primer GAG-GAAGGTAGAGAGCATCG), thyroid peroxidase (5' primer ATGAGAACACTTGGAGCTAT and 3' primer GACTTG-TATTGATGTTTCCA), thyroid stimulating hormone receptor (5' primer GCAAAGAGTGTGCGTCTCCA and 3' primer GCATCCAGCTTTGTTCCATT), Pax8 (5' primer CGTATTCCTCCTACAGTGAGG and 3' primer CTGGAACTCCTGTCACTCACA) and human primers speci®c for the RET/PTC3 breakpoint (5' primer TGGA-GAAGAGGAGCTGTATC and 3' primer CTTTCAG-CATCTTCACGG). The PCR product sizes generated were: G3pdh, 100 bp; thyroglobulin, 350 bp; thyroid peroxidase 300 bp; thyroid stimulating hormone receptor, 550 bp; Pax8, 360 bp; and RET/PTC3 breakpoint, 310 bp. Control PCR reactions performed without cDNA failed to generate any detectable products. In addition, all RNA samples were sham reverse transcribed and PCR ampli®ed to ensure that ampli®cation products were derived from cDNA and not contaminating genomic DNA (minus RT control).
Immunocytochemistry
For immunohistochemical analysis of protein expression, thyroid tissue was prepared using established protocols (Ausubel et al., 1995) . Brie¯y, thyroid glands were removed, ®xed in 10% formalin for 24 h and desiccated. Following desiccation, tissues samples were embedded in liquid paran and cooled. Paran-embedded tissue was cut into 5 mM sections and placed on silanized slides (Fisher Scienti®c). The sections were treated with xylene to remove paran and rehydrated with decreasing concentrations of alcohol and microwaved for 15 min in 100 mM citrate buer (pH 6.0). To reduce background signals, the slides were treated with 10% normal serum for 15 min. Following this blocking step, slides were incubated with a 1 : 200 dilution of a rabbit anti-human RET antibody (Santa Cruz Biologicals); speci®c for an epitope corresponding to amino acids 784 ± 801 mapping at the carboxy terminus of the RET/PTC protein (Sweetser et al., 1997) , 1 : 500 dilution of mouse monoclonal anti-human thyroglobulin (Harlan SeraLab, Loughborough, UK) or 1 : 4000 dilution of a murine Fhit polyclonal antibody (Siprashvili et al., 1997) overnight at room temperature. The following day, all slides were washed two times for 5 min each with phosphate buered saline (PBS) and once for 5 min with PBS/1% bovine serum. Samples were incubated with biotinylated secondary antibody for 1 h at room temperature, washed and incubated with substrate according to the DAB Vectastain kit (Vecto Labs, Inc.), counterstained using hematoxylin, dehydrated and mounted.
Western blot analysis
Tissues were homogenized and cells lysed in protein extract buer (30 mM Tris-Hcl, pH 8.0, 10 mM EDTA, 1% Triton X-100, 100 mM NaCl, 1 mM PMSF) and stored at 7708C. Protein extracts were separated by SDS ± PAGE and transferred to nitrocellulose membrane. The membranes were then blocked for 30 min in 5% milk in TBST buer (20 mM Tris-Hcl, pH 7.4, 135 mM NaCl, 1% Tween-20) and incubated at 48C overnight with primary anti-b-Actin (diluted 1 : 1000, Santa Cruz Biotechnology, Inc.), anti-Fhit (diluted 1 : 5000) as previously described (Siprashvili et al., 1997) or anti-thyroglobulin (diluted 1 : 1000; Zymed, Inc.) antibody. Following incubation, the membrane was washed and treated with either horseradish peroxidase (HRP)-conjugated antirabbit Ig (Promega) or anti-goat Ig (Amersham Corp.) For 1 h at room temperature. Proteins were detected using the ECL TM reagent kit (Amersham) followed by exposure to Xray ®lm to visualize the bands.
Statistical analysis
Thyroid tumors from all mice were weighed and descriptive statistics and upaired T tests performed using Statview # , SAS Institute, Inc.
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